Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05027776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05027776 · ClinicalTrials.gov record · last posted 2024-04-17

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

StatusRecruiting
PhasePhase 3
Started2021-09-15
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2021-08-25; most recent amendment 2024-04-15. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-02-23
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05027776
Lead Sponsor Shanghai Bovax Biotechnology Co., Ltd.
Collaborators: Chongqing Bovax Biopharmaceutical Co., Ltd.
Conditions HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart, CIN1, CIN2, CIN3
Enrollment 1,348 participants
Start Date 2021-09-15
Primary Completion 2023-11-22 (estimated)
Study Completion 2026-09-29 (estimated)
Updated on ClinicalTrials.gov 2024-04-17